Norverapamil

Names

[ Name ]:
Norverapamil

[Synonym ]:
N-desmethyl verapamil
Benzeneacetonitrile,a-[3-[[2-(3,4-dimethoxyphenyl)-ethyl]amino]propyl]-3,4-dimethoxy-a-(1-methylethyl)
5-[(3,4-dimethoxyphenethyl)amino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
2,8-bis(3,4-dimethoxyphenyl)-2-isopropyl-6-azaoctanenitrile
2-(3,4-Dimethoxyphenyl)-2-isopropyl-5-(3,4-dimethoxyphenethylamino)valeronitrile
D591
(+/-)Nor-methylverapamil

Biological Activity

[Description]:

Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

[Related Catalog]:

Signaling Pathways >> Membrane Transporter/Ion Channel >> Calcium Channel

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Membrane Transporter/Ion Channel >> P-glycoprotein

[Target]

Calcium channel blocker[1] P-glycoprotein (P-gp) inhibitor[2]

[In Vitro]

Norverapamil ((±)-Norverapamil) is similarly effective as verapamil at inhibiting isoniazid and rifampicin tolerance and killing of intracellular M. tuberculosis in the absence of other drugs. norverapamil, also inhibits macrophage-induced tolerance and achieves similar serum levels to verapamil[1]. Verapamil and its major metabolite Norverapamil were identified to be both mechanism-based inhibitors and substrates of CYP3A and reported to have non-linear pharmacokinetics in clinic[3].

[In Vivo]

Norverapamil (9 mg/kg; p.o.), a major metabolite of verapamil, has terminal half-life, AUC and Cmax values of 9.4 hours, 260 ng▪h/ml, and 41.6 ng/mL, respectively[4]. Animal Model: Male Sprague-Dawley rats[4] Dosage: 9 mg/kg (Pharmacokinetic Study) Administration: Oral administration Result: t1/2=9.4 hours;AUC=260 ng▪h/mL;Cmax=41.6 ng/mL.

[References]

[1]. Adams KN, et al. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis. 2014 Aug 1;210(3):456-66.

[2]. Pauli-Magnus C, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82.

[3]. Wang J et al. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013 Nov 20;50(3-4):290-302.

[4]. Choi DH, et al. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34(3-4):163-8.

Chemical & Physical Properties

[ Boiling Point ]:
586.1ºC at 760 mmHg

[ Molecular Formula ]:
C₂₆H₃₆N₂O₄

[ Molecular Weight ]:
477.03600

[ Flash Point ]:
308.2ºC

[ Exact Mass ]:
476.24400

[ PSA ]:
72.74000

[ LogP ]:
5.94378

Safety Information

[ Hazard Codes ]:
T+

Precursor & DownStream

Precursor

DownStream

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.